

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18 2026, 8:45 AM EST

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the \$3+ Billion Pancreatic Cancer Market

Feb 5 2026, 8:45 AM EST

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27 2026, 8:45 AM EST

STOCK OVERVIEW

Symbol	PPCB
Exchange	Nasdaq
Market Cap	3.33m
Last Price	\$0.21
52-Week Range	\$0.1555 - \$11.00

02/18/2026 09:00 PM EST

INVESTOR RELATIONS

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

MANAGEMENT TEAM

James Nathanielsz
CEO and Executive Chairman

Dr. Julian Kenyon, M.D.
Chief Scientific Officer

Professor Klaus Kutz, M.D.
Chief Medical Officer

Jeannine Zimmerman
Chief Financial Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.